diabetestalk.net

Cvs Insulin

A Drug Company Just Struck A Deal To Discount The Price Of A Lifesaving Diabetes Medication To $25

A Drug Company Just Struck A Deal To Discount The Price Of A Lifesaving Diabetes Medication To $25

Insulin prices have been rising — increases that mean some people are spending as much on monthly diabetes-related expenses as their mortgage payment. As a result, the companies that make insulin have been under fire from the public and politicians including US Senator Bernie Sanders. In response, one of those insulin-makers, Danish pharmaceutical company Novo Nordisk, said Thursday that it's partnered with CVS Caremark to provide $25 vials of insulin, roughly $100 less than the list price. The insulins that will be part of the deal for now are Novolin R, Novolin N and Novolin 70/30. These are human insulins, which scientists discovered in the 1970s. It uses recombinant DNA to manufacture real human insulin, so that it no longer had to come from animals. It's the precursor to a type of insulin called analogue, the most prescribed insulin at the moment. Analogue insulins are slight variations of human insulin that aim to help diabetics' bodies function more closely to how they would if they were able to produce the insulin themselves, and they tend to be more expensive than the human insulins. The $25 insulin prescription savings program is the first step as part of Novo's pledge to keep out of pocket costs low to consumers. In December 2016, Novo also said it will limit all future drug list price increases from the company to single digit percentages. "We’re committed to developing sustainable solutions with customers and will continue to pursue opportunities to ensure that patients have access to insulin that is affordable," Doug Langa, senior vice president and head of North America operations at Novo said in a news release. In December, Novo's rival, Lilly began offering more than 40% discounts off the list price of its insulins through an app called Blink Health Continue reading >>

Prescription Drug Benefit Changes For 2017 Individual Or Employer-offered

Prescription Drug Benefit Changes For 2017 Individual Or Employer-offered "metallic" Plans

New drugs are being added to the prior authorization and step therapy programs under your prescription drug benefit plan. Dispensing limits are also being added to select drugs. If your drug is part of the prior authorization program , you will need to have your doctor request pre-approval, or prior authorization, from BCBSTX before you can get benefits for select drugs. If your drug is part of the step therapy program , you will need to have a prescription history for a preferred drug before your benefit plan will cover some other drug. If your drug has a dispensing limit , you will get coverage only for what the dispensing limit allows. If you are taking, or are prescribed, a drug that is part of these new programs, or think these new programs might affect you, please talk to your doctor now. For Individual Plan Members Only: Coupons If you paid for a covered specialty prescription drug at Prime Specialty Pharmacy by using a drug manufacturer's coupon or copay card, this amount will not apply to your plan deductible or out-of-pocket maximum, unless it is a permitted third-party cost sharing payment. Remember: Treatment decisions are always between you and your doctor. Only you and your doctor can decide which medicine is right for you. Talk with your doctor, or pharmacist, about any questions or concerns you have about medicines you are prescribed. Coverage is based on the limitations and exclusions of your benefit plan. For some medicines, members must meet certain criteria before prescription drug benefit coverage may be approved. See your plan materials for details. If you have any questions, call the number on the back of your ID card. * Members with a health plan offered through their employer will see these changes on their 2017 plan renewal date, unless otherw Continue reading >>

Cvs Drops Sanofi's Diabetes Drugs For Biosimilars

Cvs Drops Sanofi's Diabetes Drugs For Biosimilars

PARIS (Reuters) - U.S. pharmacy benefit manager CVS will drop Sanofi’s main insulin drug Lantus from the list of medicines it reimburses on behalf of health insurers, dealing a blow to the French drugmaker’s key diabetes business. CVS said it would switch instead to Ely Lilly’s cheaper biosimilar drug Basaglar from 2017. Biosimilars are cheaper copies of protein-based biotech drugs such as Lantus, which are no longer protected by patents. They cannot be precisely replicated like conventional chemical drugs but have been shown to be equivalent in terms of efficacy and side effects. U.S. pharmacy benefit managers such as CVS help private-sector medical insurers negotiate better prices from drugmakers and also draw up so-called formularies, which are exclusive lists of drugs they reimburse for the insurers they work for. CVS, which has nearly 80 million plan members, announced on Tuesday a number of changes to its formulary, saying they would lead to significant savings. The company also said it would no longer reimburse Toujeo, Sanofi’s next-generation diabetes drug. Sanofi shares were down 1.4 percent at 1250 GMT. “Sanofi is disappointed by this decision. Healthcare professionals and patients should have a choice regarding their treatment,” a spokesman for the French group said in an emailed statement. “We will continue our ongoing discussions with other insurers,” he said, adding CVS’s announcement did not change the group’s forecasts. The patent on Lantus expired in 2015 in the United States, the world’s largest drugs market, and Sanofi hopes to revive declining diabetes sales with Toujeo, launched in March 2015. Switzerland’s Novartis and Actelion were also dealt blows by CVS’s new formulary. In a research note, Citi analysts said CVS’s new Continue reading >>

Novolin N Suspension For Injection Drug Information, Side Effects, Faqs

Novolin N Suspension For Injection Drug Information, Side Effects, Faqs

"Insulin is necessary for cells in the body to take in glucose. The liver both makes glucose from food and stores glucose for later use as energy.Food comes into the body and is broken down into glucose which travels through the blood to be used as energy. The liver can also make glucose if the body needs it. When glucose enters the blood, the pancreas releases the right amount of a hormone called insulin to balance the blood levels by delivering glucose into the cells that need energy and storing the extra. Problems can occur when there is no insulin, not enough insulin or the cells can"t recognize insulin and can"t use the glucose for energy. Insulin, the medication, regulates glucose the same way the hormone insulin does. Once in the bloodstream, insulin binds to insulin receptors on the cell surface. This signals the cell to send glucose transporters to the cell"s surface. This transport mechanism allows glucose be taken into the cell where it is used for energy. Removing blood glucose restores a normal balance between blood glucose and insulin." Watch a Video Showing How This Drug Works -an unusual or allergic reaction to insulin, metacresol, other medicines, foods, dyes, or preservatives Insulin is for injection under the skin. Use exactly as directed. It is important to follow the directions given to you by your health care professional or doctor. You will be taught how to use this medicine and how to adjust doses for activities and illness. Do not use more insulin than prescribed. Do not use more or less often than prescribed. Always check the appearance of your insulin before using it. This medicine should be white and cloudy. Do not use it if it is not uniformly cloudy after mixing. It is important that you put your used needles and syringes in a special Continue reading >>

Diabetes Complications: Cvs Disease

Diabetes Complications: Cvs Disease

Treating Diabetes Without Breaking Your Heart Figures from the World Health Organization show that cardiovascular diseases (CVDs), a spectrum of conditions that include coronary artery disease and cerebrovascular disease, are the leading cause of death worldwide. Dig a little deeper and you will discover the group most impacted by CVD. Adults with diabetes are two to four times more likely to suffer a heart attack or stroke than those without the disease. All of the traditional risk factors for developing heart disease—hyperlipidemia, hypertension, smoking, and obesity—are amplified in diabetics. The good news here is that aggressive management of hyperglycemia, blood pressure and dyslipidemia (abnormal amount of lipids in the blood) can significantly cut the risk of any CVD by nearly 50%! The bad news is that less than 10% of diabetics have achieved the American Diabetes Association’s recommended goals for control of blood glucose, blood pressure and cholesterol. Nonetheless, progress has been made over the past 20 years in reducing these diabetes complications, as evidenced in a recent study in the New England Journal of Medicine study. At least some of the rate reduction can be attributed to better management of major risk factors using novel therapies. For instance, the PPARγ agonists, such as rosiglitazone and pioglitazone, are insulin- sensitizing agents that allow that hormone to act more efficiently. Exenatide, a glucagon-like peptide-1 (GLP-1) mimetic, acts in a number of ways to stimulate insulin secretion, decrease appetite and suppress glucagon secretion to lower blood glucose. Sitagliptin and other members of the “gliptin” family are inhibitors of dipeptidyl peptidase-4, an enzyme that degrades GLP-1. Treatment with these agents prolongs the life Continue reading >>

Cvs Pharmacy Buys Up Aetna Insurance In Latest Consolidation Of Pharmaceutical Power

Cvs Pharmacy Buys Up Aetna Insurance In Latest Consolidation Of Pharmaceutical Power

Tap here to turn on desktop notifications to get the news sent straight to you. Echols Scholar at the University of Virginia CVS Pharmacy Buys Up Aetna Insurance In Latest Consolidation Of Pharmaceutical Power How is it legal for the company that sells me my meds to own the company that is supposed to help me afford them? 12/06/2017 07:22 pm ETUpdatedDec 07, 2017 The pharmaceutical industry is capable of marking-up drugs by up to thousands of a percent, in extreme cases. CVS, a PBM, just bought up Aetna insurance, which could either help or hurt consumers, but limits consumer choice in an already-restrictive market-place. Just how big is Big Pharma? Over half of Americans are on some kind of prescription medication. A study of 10 years worth of medical and health policy, published in JAMA last year, found that the U.S. spent $858 per capita on drugs in 2013, more than twice that of other industrialized countries. It gets even bigger when you consider all the intermediaries the FDA, Pharmacy Benefits Managers (PBMs), insurance companies, physicians between you and the pharmaceutical company that affect what you pay for a given drug. Mergers are common in the industry and occasionally get blocked by anti-trust legislation, as in Aetna insurances failed attempt to buy up fellow-insurer Humana Inc earlier in 2017. Now, Aetna is about to be swallowed up in one of the largest health care acquisitions ever, in a move that befuddles those in an already-chaotic industry. Aetna insures more the 46 million people in the U.S. myself included. It, like many insurance companies in 2017, restricts benefits to certain providers and only covers prescriptions filled through certain pharmacies. CVS pharmacies, a PBM which claims to serve 5 million customers every day, just bought Aetna i Continue reading >>

States Investigate Pharma Companies, Cvs Health As Diabetes Drug Prices Reach Record Highs

States Investigate Pharma Companies, Cvs Health As Diabetes Drug Prices Reach Record Highs

Post a comment / Oct 30, 2017 at 6:44 AM A patient loads insulin for his routine shot. With the price of a crucial diabetes drug skyrocketing, at least five states and a federal prosecutor are demanding information from insulin manufacturers and the pharmaceutical industry’s financial middlemen, seeking answers about their business relationships and the soaring price of diabetes drugs. Attorneys general in Washington, Minnesota and New Mexico issued civil investigative demands this year and are sharing information with Florida and California, according to various  corporate financial filings. Insulin makers Eli Lilly, Novo Nordisk, Sanofi and top pharmacy benefit manager CVS Health are targets in the state investigations. Several of the financial filings note that the state and federal prosecutors want information regarding specific insulins for specific dates in relation to “trade practices.” They appear to be looking into potentially anti-competitive business dealings that critics have leveled at this more than  $20  billion niche market of the pharmaceutical industry, according to analysts and court filings reviewed by Kaiser Health News. These include whether drugmakers and middlemen in the supply chain have allowed prices to escalate in order to increase their profits. At the same time, prominent class-action lawyers are bringing suits on behalf of patients. Steve Berman, an attorney best known for winning a multibillion-dollar settlement from the tobacco industry, alleged collusion and said it was time to break up the  “insulin racket.” The price of insulin — a lifesaving drug — has reached record highs as Eli Lilly, Novo Nordisk and Sanofi raised prices more than 240 percent over the past decade to often over $300 a vial today, with price rises Continue reading >>

Are You Overpaying For Your Prescription Drugs? Our Investigation Shows Why You Need To Shop Around

Are You Overpaying For Your Prescription Drugs? Our Investigation Shows Why You Need To Shop Around

You expect to find price differences when you shop for electronics or groceries, but on life saving drugs? We're not talking about what one person's insurance will pay versus another's, but the cash price being charged. The differences will not only shock you, they might make you sick. "I'll do what my mother did and die." Barbara Guzman knows that without her prescription drugs, her time is running out. Like her mom, who couldn't pay for her oxygen tanks, Barbara can't afford the seven hundred dollars it costs for her COPD, asthma and cholesterol medications. It's why she doesn't take them as prescribed. “I'm supposed to use it morning and night," she said. "I only use it in the morning. This one, I'm supposed to use morning and night. I only use it at night." What Barbara didn't know is she doesn't have to pay as much as she does. All she'd have to do is go to a different neighborhood. “It's really to the advantage of the healthcare delivery system, that patients don't know first of all what they should reasonably pay for healthcare,” said Bill Kampine of Healthcare Blue Book. Healthcare Blue Book is a website that helps consumers get the best prices--because they're in the dark. We found this out first hand after an exhaustive search, made harder when some pharmacies refused to give us prices over the phone. "Can you check on the price of a drug for me," I asked the pharmacist at one drug store. We picked 15 of the most commonly prescribed drugs on the market: Advair Diskus Bystolic Celebrex Crestor Flovent HFA 44mg Januvia 50 Lyrica 50 Namenda Spiriva Handihaler Symbicort Synthroid Tamiflu Ventolin HFA Viagra 50mg Zetia 10mg We then gathered prices from 5 popular chains: CVS, Giant Eagle, Rite Aid, Walgreens, and Walmart. We compared them for four different ne Continue reading >>

Cvs Health Launches Reduced Rx Savings Program To Give Patients Access To More Affordable Medications

Cvs Health Launches Reduced Rx Savings Program To Give Patients Access To More Affordable Medications

WOONSOCKET, R.I., March 16, 2017 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced the company will launch Reduced Rx , a prescription savings program that will offer discounts on certain medications through CVS Health's pharmacy benefits manager, CVS Caremark directly to patients. The program will help patients with high out of pocket costs afford essential medications. Novo Nordisk will participate in the prescription savings program. Through this program, CVS Health and Novo Nordisk will offer Novolin R , Novolin N and Novolin 70/30 human insulin at a cost of $25 per 10ml vial, which reflects a potential savings of as much as $100 for cash paying patients. The Reduced Rx launch follows another affordability announcement made earlier this year by CVS Health. Working with Impax Laboratories, CVS Health announced in January that it has made the authorized generic for Adrenaclick, an epinephrine auto-injector for patients with allergic reactions, available at all CVS Pharmacy locations at the lowest cash price in the market, $109.99 for a two-pack. CVS Health collaborated to create both the generic Adrenaclick offering and the Reduced Rx program in response to consumer need for low cost options. "We developed the Reduced Rx prescription savings program with Novo Nordisk because we both recognized a need and an opportunity to make critical medications more affordable for patients," said Jonathan Roberts, Executive Vice President and Chief Operating Officer, CVS Health. "This savings program will leverage CVS Caremark's expertise in providing lower cost prescription drugs and fulfill our company's purpose of helping people on their path to better health." "This program underscores how important collaboration is to addressing the affordability challenges patients face Continue reading >>

Insurers Heavily Restrict Diabetes Coverage In 2017

Insurers Heavily Restrict Diabetes Coverage In 2017

Dear Betics, ​ Nothing makes me madder than having to arduously fight the insurance bureaucracy to stay alive. And the NPR report I read today has my heart racing with indignant rage on behalf of diabetics everywhere who KNOW what a struggle it is to cry, beg and plead with the insurance company in an effort to coerce them into doing the very thing they’re charged with doing: keeping you alive and well. If you have diabetes, you probably (like me) burst into tears at least three times per year after ending a call with a customer service representative who insists your life-saving diabetes treatment isn’t covered by insurance. Before you continue reading, get your game face on, because this is going to piss you off. In 2017, diabetics who get their meds through CVS Caremark or Express Scripts are in for some blood boiling adjustments to diabetes (and other) drug coverage. NPR’s got the full story, and you can read it here. For my part, I’ll summarize the CVS diabetes drug denial list for 2017 (because it’s bigger than the Express Scripts list), and discuss why denying people the drugs they need to stay alive is so awful. Both companies are choosing to remove brand name drugs from their formulary and instead are choosing to cover generic versions. Fine. We’re all accustomed to that. That isn’t news. Substituting generic for brand name happens ALL the time. I’m not upset about that. Here’s what I AM upset about: the prescription insurers are choosing to replace some of your current meds with biosimilar medications (this happens from time to time with all insurers, but not to this degree). Replacing a drug with a biosimilar is NOT the same thing as replacing a brand name drug with a generic drug that has the exact same ingredients. In this particular con Continue reading >>

Cvs-aetna Merger: 4 Ways It Could Change Your Health Care - Cnn

Cvs-aetna Merger: 4 Ways It Could Change Your Health Care - Cnn

4 reasons why US health care is so expensive In other words, "your insurance company now cares not just what you're spending on drugs but what you're spending on overall medical utilization," Starc said. "It could be the case that they might design your benefits in a way that makes it cheaper for you to do things like fill your asthma drugs or your blood pressure medication, those types of drugs that are likely to keep you out of the hospital," she said. "That could be very beneficial for consumer health." On the other hand, if Aetna customers' pharmacy benefit provider and pharmacy services provider merge, it could be difficult for them to go outside their network for pharmacy benefits, and their pharmacy options could diminish, said Dr. Michael Williams, an associate professor of surgery at the University of Virginia and director of its Center for Health Policy, who is not involved in the merger. A 'double-edged sword' when it comes to options Consumers might find they have fewer choices about where they can get services, or what they'll pay -- but those services might be more convenient. "Certainly, if I was CVS and was in the end paying for Aetna's services, I would limit as much as I can from which pharmacy you can get your medication," said Williams, who is insured through Aetna and has treated Aetna-insured patients. "The pricing will be one that is going to change for the patient," he said. "The reality for the average consumer is that the number of choices that you're going to have if you're already insured with Aetna ... will probably diminish." This aspect of the CVS-Aetna merger could impact prescription services as well as health services provided in CVS walk-in clinics. Overall, it seems to present a double-edged sword in the health care marketplace for c Continue reading >>

Novo Nordisk And Cvs Partner To Offer $25 Insulin

Novo Nordisk And Cvs Partner To Offer $25 Insulin

CVS Health has launched their Reduced Rx Savings Program and Novo Nordisk is participating by helping make some of their insulin more affordable. This prescription savings program will give discounts on certain medications and is intended to help patients who have either a high deductible cost to deal with or those who don’t have insurance coverage. Novo Nordisk and CVS Health will be offering Novolin R, Novolin N, and Novolin 70/30 human insulin for $25 per 10ml vial. For cash paying patients this could save them as much as $100. Jonathan Roberts, the Executive Vice President and Chief Operating Officer at CVS Health said in a Novo Nordisk press release that “We developed the Reduced Rx prescription savings program with Novo Nordisk because we both recognized a need and an opportunity to make critical medications more affordable for patients,” and that “This savings program will leverage CVS Caremark’s expertise in providing lower cost prescription drugs and fulfill our company’s purpose of helping people on their path to better health.” Dough Langa, the senior vice president and head of North America Operations at Novo Nordisk said that “This program underscores how important collaboration is to addressing the affordability challenges patients face in certain health plans or who remain uninsured. We all have a role to play and that’s why we welcomed the chance to work with CVS Health on this program,” He added that, “We’re committed to developing sustainable solutions with customers and will continue to pursue opportunities to ensure that patients have access to insulin that is affordable.” This program lets patients buy medications at the reduced cost at any of the more than 67,000 pharmacies in the CVS Caremark retail network, including the Continue reading >>

Boss V Cvs Caremark - 17-cv-01823

Boss V Cvs Caremark - 17-cv-01823

Class action lawsuit filed on March 17, 2017, by Keller Rohrback on the behalf of the Type 1 Diabetes Defense Foundation. Case 2:17-cv-01823 Document 1 Filed 03/17/17 Page 1 of 315 PageID: 1Michael Critchley, Sr.Michael Critchley, Jr.CRITCHLEY, KINUM & DENOIA, LLC75 Livingston AvenueRoseland, NJ 04068Tel: (973) 422-9200Derek W. Loeser (pro hac vice forthcoming)Gretchen S. Obrist (pro hac vice forthcoming)KELLER ROHRBACK L.L.P.1201 Third Avenue, Suite 3200Seattle, WA 98101Tel: (206) 623-1900Attorneys for Plaintiffs UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEYJULIA BOSS, RUTH A. HART, RUTH Civil Action No.JOHNSON, LEANN RICE, and TYPE 1DIABETES DEFENSE FOUNDATION,on behalf of themselves and all others CLASS ACTION COMPLAINT ANDsimilarly situated, DEMAND FOR JURY TRIAL Plaintiffs, v.CVS HEALTH CORPORATION,CAREMARK RX, L.L.C., EXPRESSSCRIPTS HOLDING COMPANY,EXPRESS SCRIPTS, INC.,UNITEDHEALTH GROUP, INC.,OPTUMRX, INC., SANOFI-AVENTISU.S. LLC, NOVO NORDISK INC., andELI LILLY AND COMPANY, Defendants. Case 2:17-cv-01823 Document 1 Filed 03/17/17 Page 2 of 315 PageID: 2 TABLE OF CONTENTSI. INTRODUCTION ............................................................................................................ 1II. PARTIES ........................................................................................................................ 13 A. Plaintiffs .............................................................................................................. 13 B. Defendants .......................................................................................................... 16III. JURISDICTION AND VENUE ..................................................................................... 19IV. FACTUAL ALLEGATIONS ............................................ Continue reading >>

Cvs Health To Remove 35 Medicines From 2017 Formulary List, Including 'hyperinflationary Drugs'

Cvs Health To Remove 35 Medicines From 2017 Formulary List, Including 'hyperinflationary Drugs'

CVS Health to remove 35 medicines from 2017 formulary list, including 'hyperinflationary drugs' (Ref: Bloomberg, StreetInsider, CVS Health, Fox Business, CNBC, The Wall Street Journal, Morningstar, Channel News Asia, Express Scripts) CVS Health said that it will remove 35 products from its standard formulary for 2017, including 10 medicines that the pharmacy benefit manager described as "hyperinflationary" drugs. CVS Health indicated that it will drop Sanofi's diabetes therapy Lantus (insulin glargine) and Amgen's cancer drug Neupogen (filgrastim) in favour of biosimilar versions of the medicines for many of its drug-plan members. "We want to signal that this biosimilar movement is real," remarked CVS Health chief medical officer Troyen A. Brennan, adding "we have big hopes for [biosimilars] to reduce drug costs overall." Brennan suggested that biosimilars are typically priced 10 percent to 15 percent cheaper than the originator products, although the executive indicated that CVS Health has negotiated additional discounts. Last year, the FDA approved Eli Lilly's Basaglar (insulin glargine), marking the first approval of an insulin product through the FDA's 505(b)(2) regulatory pathway. The therapy, which was developed as part of an alliance with Boehringer Ingelheim, has an identical amino acid sequence to Lantus. Meanwhile, Novartis' Sandoz unit launched the biosimilar Zarxio (filgrastim-sndz) in 2015 at a 15-percent discount to Neupogen. In response to the news, a spokeswoman for Amgen said Neupogen "is competitively priced," adding that patients and doctors should be able to choose which product they want to use. A Sanofi spokesman said CVS Health's decision to exclude Lantus and another of the company's insulins would make "it difficult for patients to benefit from Continue reading >>

Cvs, Novo Nordisk Partner To Make Insulin More Affordable

Cvs, Novo Nordisk Partner To Make Insulin More Affordable

CVS, Novo Nordisk Partner to Make Insulin More Affordable Novo Nordisk just lowered the cost of some insulin brands. Will other Rx companies follow? To put it mildly, prescription drug prices are surging. Some of the most egregious examples of price-gouging fueled anger that help buoy U.S. Sen. Bernie Sanders’ insurgent presidential campaign last year. Absurdities such as laws that prohibit Medicare and other healthcare programs from negotiating drug prices explain the constant increase in the cost of pharmaceuticals, though some analysts say the dynamics between industry, healthcare providers and government indicate that changing these policies change may not necessarily work. Other tactics, such as a more stringent enforcement of U.S. patent law, have been suggested in Congress. Even President Donald Trump called for action on skyrocketing drug costs – though his fractious relationship with Congress could get in the way of significant change at the policy level. But at a time when advertising revenues on television are stagnant or even declining, pharmaceutical companies continue to spend billions on commercials – and it’s fueling the rise in drug prices. Despite the drug companies’ insistence that they need to charge these prices to cover their research and development costs, Ana Swanson of the Washington Post argued two years ago that 9 out of 10 large pharmaceutical firms spent more on marketing than scientific research. Watch television during one of the few remaining soap operas or the networks’ evening news, and the evidence suggests those trends have not budged much. Nevertheless, public pressure and outrage could nudge more companies to become more conscious about their impact on public health, notably by changing how they market and price some Continue reading >>

More in insulin